HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.

Abstract
We successfully treated a child with parkinsonism secondary to cytosine arabinoside with levodopa/carbidopa and attempted to elucidate the pathogenesis of the disorder by sequential analysis of cerebrospinal fluid biogenic amines, sequential magnetic resonance imaging, and fluorodopa positron emission tomography, which revealed both permanent and reversible biochemical and structural alterations. The parkinsonian disorder resolved in 9 months. Metabolic changes and structural abnormalities on imaging studies were chronologically correlated with the clinical course.
AuthorsAbe M Chutorian, Aviva Bojko, Linda Heier, Steven Frucht, Toby Nygaard, David Edelberg
JournalJournal of child neurology (J Child Neurol) Vol. 18 Issue 11 Pg. 812-5 (Nov 2003) ISSN: 0883-0738 [Print] United States
PMID14696914 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antiparkinson Agents
  • Cytarabine
  • Levodopa
  • Carbidopa
Topics
  • Antimetabolites, Antineoplastic (adverse effects)
  • Antiparkinson Agents (administration & dosage)
  • Carbidopa (administration & dosage)
  • Child
  • Cytarabine (adverse effects)
  • Humans
  • Levodopa (administration & dosage)
  • Male
  • Parkinson Disease, Secondary (chemically induced, drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: